If interested, please click I am Interested above. This will take you to an additional survey on the participate page, which must be filled out in order for researchers to receive your contact information. Otherwise, please use the contact information at the bottom of the page to contact the researcher directly

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

This study is a prospective, multi-center, randomized, double-blind placebo-controlled study
of subjects receiving the HM II LVAD as per the current FDA approved indications for use.

Eligibility Criteria

Inclusion Criteria

- Subject is receiving the HM II per standard of care (SOC) in accordance with the FDA
approved indications for use

- Subject is ≥ 60 years of age

- Subject is receiving the HM II as their first LVAD

- Subject or legally authorized representative (LAR) has signed an informed consent
form (ICF).

Exclusion Criteria

- Existence of ongoing mechanical circulatory support (MCS) other than intra-aortic
balloon pump

- Participation in any other clinical investigation(s) involving an MCS device, or an
investigation(s) that is likely to confound study results or affect study outcome

- Antiplatelet therapy is mandated for other conditions, in particular: a) recent
coronary artery stenting (≤ 6 months), b) carotid artery disease, and c) other
conditions where the investigator is not comfortable leaving subjects off-ASA or
starting ASA post LVAD implantation. In situations where the investigator is
uncertain, the Steering Committee can provide recommendation to the investigator as
needed.

- Subjects in whom heart transplantation is expected in ≤ 6 months

- Subjects with a known ASA allergy

Principal Investigator

Travis Abicht, M.D.

Study Contact

Carrie Vooght, cvooght@sjm.com, 781-852-8354

Estimated Completion Date

Thursday, October 1, 2020

ClinicalTrials.gov #

NCT02836652
03/23/2017